Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...

Jean Trebek, Lisa Swayze, Joan Vassos, Stephen Nichols, Jeff Mauro, Jonathan Frakes, Kitty Swink, Rosa Blasi and Many More Raise [...] READ MORE ...

A team of researchers from Taiwan has developed PanMETAI, an AI-powered platform that analyzes metabolic fingerprints in a ...

Breta Hasimi struggled to speak when she received the diagnosis of triple-negative breast cancer, one of the most aggressive forms of cancer. Her worst fears were becoming reality. Aware that her ...

Carolyn Gusoff has covered some of the most high profile news stories in the New York City area and is best known as a trusted, tenacious, consistent and caring voice of Long Island's concerns. For ...

The FDA gave the go-ahead to Novocure for its tumor-treating electric fields device that targets advanced pancreatic cancer in conjunction with the drugs gemcitabine and nab-paclitaxel. The approval ...

A new UCLA investigator-initiated study sponsored by the UCLA Health Jonsson Comprehensive Cancer Center has found that adding immunotherapy to standard chemotherapy before surgery is safe and shows ...

TAMPA, Fla. (WFLA) — A first-of-its-kind device for pancreatic cancer treatment has been approved by the U.S. Food and Drug Administration. The FDA announced Thursday that the device, Optune Pax, ...

The FDA has approved a first-of-its-kind wearable electrical device — Optune Pax (Novocure) — for patients with locally advanced pancreatic cancer, in combination with gemcitabine and nab-paclitaxel.

FDA approved Optune Pax with gemcitabine/nab-paclitaxel, applying alternating electric fields to disrupt mitosis via abdominal arrays, expanding noninvasive, home ...

The FDA approved a tumor treating fields (TTFields) device for locally advanced pancreatic cancer, the first therapy approved in this setting in nearly 30 years. Dubbed Optune Pax, the wearable device ...

Stress signals redesign tissues during inflammation and cancer. Left: Normal tissue maintenance. Right: Stress signals “switch on” fibroblasts, turning them into myCAFs (purple) that actively recruit ...